Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial
Olaratumab in combination with doxorubicin missed the phase III ANNOUNCE trial’s primary endpoint of overall survival and did not confirm a clinical benefit for patients with advanced or metastatic soft tissue sarcoma compared with standard doxorubicin.
Source: OncLive